Takeda Pharmaceutical (TYO:4502) and Portal Instruments said today that the pair inked a collaboration to develop and commercialize Portal’s needle-free drug delivery device with Takeda’s biologic medicines.
The first development program is slated to combine Takeda’s monoclonal antibody for adults with moderately- to severely-active ulcerative colitis or Crohn’s disease with Portal’s technology. The investigational therapy is currently administered through intravenous infusion, according to Takeda.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!